Cargando…
Sacituzumab Govitecan for Treatment of Refractory Triple-Negative Metastatic Breast Cancer
Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triplenegative breast cancer who received at least two prior therapies for metastatic disease. A confirmatory phase III trial evaluating sacituzumab govitecan vs. chemo...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504932/ https://www.ncbi.nlm.nih.gov/pubmed/34671504 http://dx.doi.org/10.6004/jadpro.2021.12.7.8 |